<div id="readability-page-1"><p>IFP Advisors Inc lowered its holdings in shares of  Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) by 47.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,358 shares of the company's stock after selling 76,563 shares during the period. IFP Advisors Inc owned approximately 0.22% of Orchestra BioMed worth $229,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Orchestra BioMed</strong> alerts:</span></p></div><p>A number of other hedge funds have also added to or reduced their stakes in the business. Nuveen LLC acquired a new position in shares of  Orchestra BioMed during the first quarter worth approximately $179,000.  Deutsche Bank AG increased its stake in  Orchestra BioMed by 67.3% during the 1st quarter. Deutsche Bank AG now owns 20,219 shares of the company's stock valued at $87,000 after purchasing an additional 8,134 shares in the last quarter.  Finally, Bank of America Corp DE raised its holdings in  Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company's stock worth $95,000 after buying an additional 7,036 shares during the last quarter. 53.20% of the stock is currently owned by institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>A number of research firms have recently weighed in on OBIO. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Orchestra BioMed in a report on Wednesday, October 8th. HC Wainwright dropped their price objective on Orchestra BioMed from $12.00 to $10.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, September 4th. Chardan Capital  reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Wednesday, August 13th. Finally, BTIG Research  reiterated a &#34;neutral&#34; rating on shares of Orchestra BioMed in a research note on Wednesday, August 20th. One research analyst  has rated the stock with a Strong Buy rating, three have assigned  a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $13.50.</p><p><b>View Our Latest Stock Analysis on OBIO</b></p><h2>Insider Buying and Selling</h2><p>In other Orchestra BioMed news, insider David P. Hochman bought 20,000 shares of the business's stock in a transaction on Monday, August 4th. The stock was purchased at an average price of $2.75 per share, for a total transaction of $55,000.00. Following the completion of the transaction, the insider directly owned 349,331 shares of the company's stock, valued at $960,660.25. This trade represents a 6.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have bought 37,760 shares of company stock worth $100,384 over the last quarter. 8.10% of the stock is owned by corporate insiders. </p><h2>Orchestra BioMed Trading Up 0.5%</h2><p>NASDAQ OBIO opened at $3.68 on Friday. The business's fifty day moving average is $2.71 and its 200-day moving average is $2.85. The company has a debt-to-equity ratio of 48.76, a current ratio of 2.10 and a quick ratio of 2.09. The stock has a market capitalization of $142.20 million, a price-to-earnings ratio of -2.01 and a beta of 0.60. Orchestra BioMed Holdings, Inc. has a one year low of $2.20 and a one year high of $6.50. </p><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.01. Orchestra BioMed had a negative net margin of 2,367.49% and a negative return on equity of 289.42%. The firm had revenue of $0.84 million for the quarter, compared to analysts' expectations of $0.78 million.  Equities research analysts predict that  Orchestra BioMed Holdings, Inc. will post -1.66 EPS for the current year. </p><h2>Orchestra BioMed Company Profile</h2> (Free Report)<p>Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.</p><h2>See Also</h2><ul><li>Five stocks we like better than Orchestra BioMed</li><li>What is a Stock Market Index and How Do You Use Them?</li><li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li><li>NYSE Stocks Give Investors a Variety of Quality Options </li><li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li><li>Where to Find Earnings Call Transcripts</li><li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li></ul><p><strong>Want to see what other hedge funds are holding OBIO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2><p>Before you consider Orchestra BioMed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OBIO

<p>IFP Advisors Inc reduced its stake in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) by 47.3% in Q2, now holding 85,358 shares valued at $229,000. Other hedge funds have also adjusted their positions. Analysts have mixed ratings on OBIO, with an average price target of $13.50. Insider David P. Hochman purchased 20,000 shares recently. The stock is currently trading at $3.68, with a market cap of $142.20 million and a negative EPS of -$0.50 for the last quarter.</p>

IFP Advisors Inc Has $229,000 Position in Orchestra BioMed Holdings, Inc. $OBIO